

Last logoff: 05jun95 09:23:17

Logon file001 06jun95 13:01:42

ANNOUNCEMENT **** ANNOUNCEMENT **** ANNOUNCEMENT

***New: Drug Data Report (File 452)

Derwent Drug Registry File (File 375)

***Removed: D&B Asia-Pacific Dun's Market Identifiers (File 522) --

use D&B International Dun's Market Identifiers

(File 518) for information previously found in 522.

D&B Million Dollar Directory (File 517) -- use D&B Dun's

Market Identifiers (File 516) for information

previously found in 517.

Starting June 1, 1995, the Internet e-mail delivery fee will be reduced to \$.50 per request. Also beginning on June 1, 1995, there will be a new fee of \$.01 per record for delivery of DIALOG Alert results via postal mail.

Message from database supplier:

MEDLINE and CANCERLIT erroneously annotated certain articles authored or co-authored by Dr. Bernard Fisher with the phrase "scientific misconduct--data to be reanalyzed." All such annotations have been removed or are being removed. We apologize for any problems or concerns this may have caused. Users should disregard those prior annotations.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

>>> Announcements last updated for 2june95 <<<

* * * File 047/647 has been consolidated... use B047 * * *

* * * File 148/648 has been consolidated... use B148 * * *

File 1:ERIC 1966-1995/May

(c) format only 1995 Knight-Ridder Info

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

?b 351

06jun95 13:01:59 User208669 Session B255.1

\$0.12 0.004 Hrs File1

\$0.12 Estimated cost File1

\$0.05 SPRNTNET

\$0.17 Estimated cost this search

\$0.17 Estimated total session cost 0.004 Hrs.

File 351:DERWENT WPI 1981-1995/UD=9520;UA=9515;UM=9511

(c)1995 Derwent Info Ltd

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

?s py=1981:1084

S1 1152143 PY=1981:1984

?s vaccinia

S2 297 VACCINIA

?s s1 and s2

1152143 S1

BEST AVAILABLE COPY

S3 31 S1 AND S2
?t s3/6/1-31

3/6/1

004138061 WPI Acc No: 84-283601/46

XRAM Acc No: C84-120300

New 2-alkylamino-4,6-dihalo-pyrimidine derivs. having antiviral activity against e.g. Herpes genitalis and Marek's disease

3/6/2

004073655 WPI Acc No: 84-219196/35

Related WPI Accession(s): 84-147655; 93-159478

XRAM Acc No: C84-092459

Vaccinia virus recombinant contg. influenza HA gene - useful in vaccines for prodn. of high antibody levels to influenza HA

3/6/3

004059440 WPI Acc No: 84-204981/33

XRAM Acc No: C84-086248

Physiologically active substance extracted from animal tissue infected with vaccinia virus or its culture cell

3/6/4

004057471 WPI Acc No: 84-203012/33

Related WPI Accession(s): 85-039482

XRAM Acc No: C84-095223

Aphidicolin derivs. - useful as antiviral and antitumour agents

3/6/5

003982024 WPI Acc No: 84-127568/21

XRAM Acc No: C84-053903

4-Sulpho-alkylamino-2,6-dihalo-pyrimidine derivs useful as antiviral agents

3/6/6

003867416 WPI Acc No: 84-012944/03

XRAM Acc No: C84-005457

Xyloside(s) and lyxoside(s) of purine and pyrimidine bases compsn. active against DNA viruses, such as herpes, pox viruses and adenoviruses

3/6/7

003788119 WPI Acc No: 83-784348/41

XRAM Acc No: C83-097608

Azole-carboxamide adenosine dinucleotide cpds. with antiviral and antitumour activities

3/6/8

003782168 WPI Acc No: 83-778395/40

XRAM Acc No: C83-095027

2-Beta-Ribofuranosyl- selenazole-4-carboxamide nucleoside and nucleotide(s) having in-vivo antitumour and in-vitro antiviral activity

3/6/9

003757088 WPI Acc No: 83-753299/35

XRAM Acc No: C83-084329

4'-Acridinylamino methanesulphono-m-anisidide beta-glycero-phosphate

3/6/10

003746175 WPI Acc No: 83-742376/34

XRAM Acc No: C83-079496

Antibiotic AM-2604-A produced by Streptomyces strain with
coccidiostatic, trichomonocidal, antifungal and antiviral activity

3/6/11

003710873 WPI Acc No: 83-707055/28

Related WPI Accession(s): 88-056484; 89-130047; 92-175125; 92-268664;
93-026900

XRAM Acc No: C83-064886

Vaccinia virus modified with exogenous DNA in vaccinia genome - useful
for vaccination of animals to form antibodies to coded antigens;
DEOXYRIBONUCLEIC ACID

3/6/12

003698653 WPI Acc No: 83-58636K/24

XRAM Acc No: C83-056995

Racemic 3-deazaaristeromycin useful as antiviral agent against Herpes
simplex type I, HL-23C type virus and Vaccinia virus

3/6/13

003660116 WPI Acc No: 83-20099K/09

XRAM Acc No: C83-019598

Tromantadine phosphono-acetate salt useful as antiviral agent, esp.
against herpes; DI METHYLAMINO ETHOXY ACETAMIDO ADAMANTANE VACCINIA

3/6/14

003644941 WPI Acc No: 83-04955K/03

XRAM Acc No: C83-004892

Phosphinyl-propionic and -butyric acid cpds. useful as intermediates to
herbicides, one cpd. also having antiviral activity

3/6/15

003536089 WPI Acc No: 82-84082E/40

XRAM Acc No: C82-E84082

Antivirus vaccine consisting of virus conjugated with saccharide giving
reduced prodn. of allergenic type e immunoglobulin (J5 23.8.82)

3/6/16

003528494 WPI Acc No: 82-76482E/36

XRAM Acc No: C82-E76482

2,3-Dihydro-2-oxo-1H-imidazole- 4-carboxaldehyde cpds. useful as
selective herbicides, also having antiviral antifungal and plant growth
regulating activity

3/6/17

003491426 WPI Acc No: 82-39389E/20

XRAM Acc No: C82-E39389

Virustatic 3-phenyl-4-cyano-5-amino-isoxazole derivs. prepd. from
tricyano-vinyl aniline and hydroxylamine

3/6/18

003450659 WPI Acc No: 82-05111J/49

XRAM Acc No: C82-J05111

derivs. of 1-isopropyl-amine derivs. useful as antiviral agents

3/6/19

003445004 WPI Acc No: 82-02286E/02

XRAM Acc No: C82-E02286

Compsn. contg. 1-phenyl-5-amino-1-penten-3-one derivs. useful as topical antivirals esp. for herpes infections; PENTENONE

3/6/20

003234322 WPI Acc No: 81-94880D/51

XRAM Acc No: C81-D94880

5-Phenyl-6-amino pyrazolo-pyrazine derivs. useful as antiviral agents against rhino, influenza and vaccinia viruses

3/6/21

003229065 WPI Acc No: 81-89624D/49

XRAM Acc No: C81-D89624

N-Solanesyl nitrogen heterocyclic cpds. having interferon inducing action, useful as antiviral and antitumour agents

3/6/22

003226957 WPI Acc No: 81-87515D/48

XRAM Acc No: C81-D87515

Antiviral antibiotic AM-2722 prepd. by culturing Streptomyces sp. aerobically, also has antifungal and anti-yeast activity

3/6/23

003225276 WPI Acc No: 81-85834D/47

XRAM Acc No: C81-D85834

Antiviral and antitumour nonaprenylamine derivs. contg. n-opt.substd.alkyl or alkenyl or n-cycloalkyl substit.

3/6/24

003219097 WPI Acc No: 81-79655D/43

XRAM Acc No: C81-D79655

Antibiotic A-33853 prodn. by cultivation of Streptomyces NRRL 12068; ANTIBACTERIAL ANTIFUNGAL ANTIVIRAL ANTIPROTOZOAL LARVA

3/6/25

003217439 WPI Acc No: 81-77997D/43

XRAM Acc No: C81-D77997

Compsn. contg. attenuated strain of vaccinia virus useful as cellular immunopotentiator and immune antitumour agent; TUMOUR

3/6/26

003209176 WPI Acc No: 81-69728D/38

XRAM Acc No: C81-D69728

9-Beta-hydroxy-ethoxy-methyl-guanine monophosphate useful as antiviral esp. DNA and RNA viruses

3/6/27

003185856 WPI Acc No: 81-46407D/26

XRAM Acc No: C81-D46407

Antiviral decaprenylamine derivs. contg. a pyridyl, phenyl, pyridyl-alkyl or phenyl-alkyl gp.

3/6/28

003185855 WPI Acc No: 81-46406D/26

XRAM Acc No: C81-D46406

Antiviral n-decaprenyl-heterocyclic cpds. prepd. from decaprenol
derivs. and heterocyclic amine(s)

3/6/29

003179492 WPI Acc No: 81-40043D/22

XRAM Acc No: C81-D40043

Antiviral C-5 substd. cytosine nucleoside(s) prepd. from C-5 mercurated
cytosine nucleoside(s); HERPES SIMPLEX

3/6/30

003155441 WPI Acc No: 81-15983D

XRAM Acc No: C81-D15983

Antitumour and immunostimulant cpd. from Acinetobacter by cultivation,
then treating initial prod. with barium hydroxide; ANTI VACCINIA
ANTIINFLAMMATORY ANTISECRETORY

3/6/31

003151130 WPI Acc No: 81-11669D/07

XRAM Acc No: C81-D11669

5-(Trifluoro)propenyl-substd. uracil nucleoside cpds. having antiviral
and anti-neoplastic activity with low cytotoxicity; TRI FLUORO

?t s3/7/2 11 25

3/7/2

DIALOG(R)File 351:DERWENT WPI

(c)1995 Derwent Info Ltd. All rts. reserv.

004073655 WPI Acc No: 84-219196/35

Related WPI Accession(s): 84-147655; 93-159478

XRAM Acc No: C84-092459

Vaccinia virus recombinant contg. influenza HA gene - useful in
vaccines for prodn. of high antibody levels to influenza HA

Patent Assignee: (USSH) US DEPT HEALTH & HUMAN

Author (Inventor): MACKETT M; MOSS B; SMITH G L

Number of Patents: 001

Number of Countries: 001

Patent Family:

CC Number	Kind	Date	Week	
US 6555811	A	840605	8435	(Basic)

Priority Data (CC No Date): US 555811 (831128)

Abstract (Basic): US 6555811 A

Vaccinia virus recombinant contg. the influenza HA gene. It is
used in vaccines for inoculation of animals. Hepatitis B virus
recombinant is similarly used.

USE/ADVANTAGE - The infectivity and wide host range of the
original virus are retained. Animals inoculated intradermally with the
vaccinic virus recombinant develop high levels of antibodies to
influenza HA. Animals inoculated intradermally with the hepatitis B
virus recombinant develop antibodies to hepatitis B. Dwg.0/3

Derwent Class: B04; D16;

Int Pat Class: A61K-000/01

3/7/11

DIALOG(R)File 351:DERWENT WPI

(c)1995 Derwent Info Ltd. All rts. reserv.

003710873 WPI Acc No: 83-707055/28

93-026900

XRAM Acc No: C83-064886

Vaccinia virus modified with exogenous DNA in vaccinia genome - useful for vaccination of animals to form antibodies to coded antigens;

DEOXYRIBONUCLEIC ACID

Patent Assignee: (HEAL-) HEALTH RES INC

Author (Inventor): PANICALI D; PAOLETTI E

Number of Patents: 013

Number of Countries: 018

Patent Family:

CC Number	Kind	Date	Week	
EP 83286	A	830706	8328	(Basic)
AU 8291806	A	830630	8333	
JP 58129971	A	830803	8337	
DK 8205724	A	830829	8341	
ZA 8209386	A	830822	8348	
IL 67537	A	860228	8623	
US 4603112	A	860729	8633	
US 4769330	A	880906	8838	
IT 1165451	B	870422	8935	
EP 83286	B	900307	9010	
DE 3280128	G	900412	9016	
IT 1191150	B	880224	9051	
JP 94071429	B2	940914	9435	

Priority Data (CC No Date): US 334456 (811224); US 446824 (821208); US 622135 (840619)

Applications (CC,No,Date): EP 82402380 (821223); JP 82234860 (821224)

Language: English

EP and/or WO Cited Patents: 8.Jnl.Ref; EP 74808; No-SR.Pub; 7.Jnl.Ref

Designated States

(Regional): AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

Filing Details: JP94071429 Based on JP58129971

Abstract (Basic): EP 83286 A

Vaccinia virus modified by the presence of exogenous DNA in the vaccinia genome is new.

Biologically pure cultures of vaccinia virus VTK-79 (ATCC VR 2031) and VTK-79L are new.

Immunisation of a host animal susceptible to vaccinia virus is effected by inoculation with a vaccinia virus having, within the vaccinia genome, DNA exogenous to the genome and coding for an antigen that will induce the animal to develop antibodies against it.

Method for the in vivo recombination of a vaccinia virus and donor DNA comprises contact of a cell monolayer with a cell-compatible medium contg. the vaccinia virus and with a similar medium contg. the donor DNA. The donor DNA comprises DNA to be introduced into the vaccinia genome present in a DNA segment otherwise co-linear with DNA present in the genome of the virus in a non-essential region of the genome.

Vaccines contg. the modified virus can be used to immunise mammals so that an approp. antibody response is elicited. Lukaryotic cells of biological prods. other than antigens can be produced. Human and animal individuals and populations may have missing genes or genetic material (for modification, replacement or repair of defective genes) introduced.

Abstract (US): 8838 US 4769330

Prodn. of vaccinia virus mutants comprises in vivo recombination of vaccinia virus DNA with heterologous DNA by infecting a host cell with vaccinia virus in a suitable medium, in the presence of a heterologous DNA which is flanked by sequences that are homologous with portions of the vaccinia genome, so that the donor DNA is introduced into the vaccinia genome, and isolation of the propagated vaccinia virus mutant.

USE - The prods. are components for vaccines which induce the formation of antigenic proteins. @ (20pp) @ 8633 US 4603112

recombinant vaccinia virus is synthetically modified by DNA not naturally occurring in the virus in a non-essential region of its genome. Pref. DNA is expressed in a host by prodn. of a protein (esp. an antigen). DNA is a gene of herpes simplex expressed in a host by prodn. of thymidine kinase, and is free of vaccinia gene producing such enzyme. Antigen is influenza virus haemagglutinin. ADVANTAGE - Can be used for inoculation so that virus replicates with inoculated individual to be immunised, thus amplifying the antigenic determinant in vivo. @ (40pp)@

Abstract (EP): 9010 EP 83286

A recombinant vaccinia virus characterised in that it contains in a non-essential region of the vaccinia genome a DNA segment which does not naturally occur in vaccinia viruses and which (a) is expressed in a vaccinated mammal and encodes an antigen which is capable of inducing an anti-body response; or (b) is expressed in infected eukaryotic cells or host organisms and encodes an antigen or a biological product other than an antigen; or (c) is capable of modifying, replacing or repairing defective genes in the infected eukaryotic cell or organism. @ (59pp)@

Derwent Class: B04; D16;

Int Pat Class: A61K-039/00; C07H-021/04; C12N-005/10; C12N-007/01; C12N-015/33; C12N-015/86; C12P-021/00; C12R-001/91; C12P-021/00 C12R-001-92

3/7/25

DIALOG(R)File 351:DERWENT WPI

(c)1995 Derwent Info Ltd. All rts. reserv.

003217439 WPI Acc No: 81-77997D/43

XRAM Acc No: C81-D77997

Compsn. contg. attenuated strain of vaccinia virus useful as cellular immunopotentiator and immune antitumour agent; TUMOUR

Patent Assignee: (ARAK/) ARAKAWA S

Author (Inventor): SEKI T; HARADA; H; NINOMIYA M; MATSUOKA H B J; ARAKAWA S

Number of Patents: 003

Patent Family:

CC Number	Kind	Date	Week	
EP 37441	A	811014	8143	(Basic)
US 4315914	A	820216	8209	
EP 37441	B	840509	8420	

Priority Data (CC No Date): EP 80300731 (800310); US 137502 (800404)

Language: English

EP and/or WO Cited Patents: DE 2145477; FR 2353641; GB 1520200; US 4108983; GB 1517540; US 4017359; BE 636102; 4.Jnl.REF

Designated States

(Regional): CH; FR; GB

Abstract (Basic): Compsn. contains an attenuated strain of vaccinia virus without capacity to form pocks in rabbits but that shows reduced humoral and enhanced cellular immune activity in mice, together with a carrier. The strain is obtd. by serial passages of the vaccinia virus in chick embryo cell monolayer culture, opt. after passage in mouse kidney cell monolayer culture. Also vaccinia virus AS strain ATCC VR-2010 is new.

The compsn. is useful as cellular immunopotentiator and immune antitumour agent for use in animals and humans. Dose is 0.001-0.1 ml virus prepn. having a virus titre of 2 times 10 power 8 PFU/ml daily. (34pp)

Abstract (EP): 8420 EP 37441

Pharmaceutical compsn. comprises an attenuated strain of live or inactivated Vaccinia virus, ATCC VR-2010, having very little pathogenicity, a much reduced humoral immunity but almost unchanged or an enhanced cell immunity; dispersed with the usual carriers and additives.

Prepn. of the strain comprises at least 100 pref. 115 successive propagations of the virus in mouse kidney cell monolayer cultures at 33-37 deg. and then five or more successive propagations in chick

embryo cell monolayer cultures at 33-37 deg.

The compsns. are used as cellular immunopotentiators and immune anti-tumour agents. @ (9pp)@

Derwent Class: B04; D16;

Int Pat Class: A61K-035/76; A61K-045/05; C12N-007/08; A61K-039/28

?s pox?

S4 291 POX?

?ds

Set	Items	Description
S1	1152143	PY=1981:1984
S2	297	VACCINIA
S3	31	S1 AND S2
S4	291	POX?

?s s1 and s4 not s3

1152143 S1

291 S4

31 S3

S5 35 S1 AND S4 NOT S3

?t s5/6/1-35

5/6/1

004291354 WPI Acc No: 85-118232/20

XRAM Acc No: C85-094538

XRPX Acc No: N85-088946

Base for high density magnetic recording medium comprises discontinuous film formed on one side of thermoplastic resin film

5/6/2

004209196 WPI Acc No: 85-036076/06

XRAM Acc No: C85-015799

Vaccine prepn. against avian pox-diphtheria by inoculating columnar stem into embryonated eggs, triturating membrane, sonic vibration, re-dispersion and lyophilising

5/6/3

004071580 WPI Acc No: 84-217121/35

Related WPI Accession(s): 84-218988

XRAM Acc No: C84-091596

Antiviral agent contg. pentagalloyl glucose

5/6/4

004042611 WPI Acc No: 84-188153/30

XRAM Acc No: C84-079296

XRPX Acc No: N84-140737

Immunisation of birds by embryonal vaccination during last quarter of incubation period when embryo has achieved immunological competence

5/6/5

004023192 WPI Acc No: 84-168734/27

XRAM Acc No: C85-069731

Esterification of carboxylic acids with alcohol(s) using 1,3-dialkyl-2-halo-3,4-tetrahydro pyridinium halide(s) as condensing agents; MEDICINE

5/6/6

004002113 WPI Acc No: 84-147655/24

Related WPI Accession(s): 84-219196

XRAM Acc No: C84-062383

Vector-contg. chimeric gene prepn. - for use in expression of foreign genes

5/6/7

003976446 WPI Acc No: 84-121990/20

XRPX Acc No: N84-090322

Tracheostomy tube with disposable inner cannula has coupling connector for releasable attachment to outer cannula mounted on proximal end of inner cannula by over-moulding

5/6/8

003962688 WPI Acc No: 84-108232/18

XRAM Acc No: C84-045736

2-(4-Chlorophenoxyethyl)-3-dimethyl-1-triazolyl-2,2-butanol with antiviral and cyto-protective properties esp. effective against lipid contg. viruses e.g. herpes (BE 20.4.84); CHLORO PHENOXY METHYL

5/6/9

003949390 WPI Acc No: 84-094934/15

Related WPI Accession(s): 84-005841; 85-316810

XRAM Acc No: C84-040488

Inactivating lipid virus in protein carrier esp. hepatitis in blood, by treatment with halocarbon

5/6/10

003924781 WPI Acc No: 84-070325/12

XRAM Acc No: C84-030047

Topical compsn for treatment of herpes simplex viral infections comprises emulsion of diethyl ether in coconut oil carrier

5/6/11

003879362 WPI Acc No: 84-024900/05

XRAM Acc No: C84-010562

Antiviral hexopyranose peptide derivs. which are muramyl peptide cpds. carrying a phospholipid residue (BE 25.1.84); HEXOPYRANOSIDE

5/6/12

003821571 WPI Acc No: 83-817818/46

XRAM Acc No: C83-111610

XRPX Acc No: N83-204926

High sensitivity multilayer analytical element comprises liq. impermeable light transmitting carrier, reagent located on face of carrier, and porous developing layer; POLYMETHYLENE TEREPHTHALATE POLYTEREPHTHALATE POLYSTYRENE POLYACRYLATE POLYMETHACRYLATE

5/6/13

003793504 WPI Acc No: 83-789741/42

XRPX Acc No: N83-183462

Recognising diverse dielectric materials by microwaves using resonator containing detector and sensors arranged on both sides of closable aperture

5/6/14

003710415 WPI Acc No: 83-706597/28

XRAM Acc No: C83-064657

XRPX Acc No: N83-119620

Water-soluble thioalkyl or sulpho-alkyl salt of phenolic resin for coating compsn., esp. for metal container; POLYPHENOL

5/6/15
003701270 WPI Acc No: 83-61254K/25
XRAM Acc No: C83-059472
Olefin polymerisation catalyst obtd. by reacting organo-magnesium cpd.
oxygen or nitrogen cpd. transition metal cpd. and reducing halide;
POLYOLEFIN

5/6/16
003539960 WPI Acc No: 82-87953E/41
Related WPI Accession(s): 82-94918E
XRAM Acc No: C82-E87953
3,6-Dihydroxy-5-beta-cholest-5-ene derivs. - useful as intermediates
for 24,25-dihydroxy-cholesterol; CHOLESTENE

5/6/17
003529569 WPI Acc No: 82-77559E/37
XRAM Acc No: C82-E77559
Mixed virus live vaccine prodn. by mixing attenuated rubella, measles
and/or mumps virus with attenuated chicken pork virus

5/6/18
003524590 WPI Acc No: 82-72576E/35
XRAM Acc No: C82-E72576
Reactive double bond-contg. phosphate derivs. used as polymerisable
fillers for hard human tissue e.g. teeth or bones

5/6/19
003510491 WPI Acc No: 82-58471E/28
XRAM Acc No: C82-E58471
Antiviral agents for external use, comprising eugenin used in
treatment of herpes, water pox and warts

5/6/20
003503338 WPI Acc No: 82-51311E/25
XRAM Acc No: C82-E51311
Physiologically active substance NSQ obtd. by extracting pox-yielding
tissue, contacting extract with adsorbent, eluting etc.

5/6/21
003502922 WPI Acc No: 82-50895E/25
XRAM Acc No: C82-E50895
Jcv-80 obtd. from inflammatory tissue resulting from tumour cell
transplantation has immune regulating activity, antitumour activity and
ulcer inhibiting actions

5/6/22
003487246 WPI Acc No: 82-35208E/17
XRAM Acc No: C82-E35208
Unsatd. carboxylic acid or ester prodn., esp. acrylate by condensation
with formaldehyde using phosphate catalyst

5/6/23
003465960 WPI Acc No: 82-13904E/08
XRAM Acc No: C82-E13904
Prepn. of a phosphorus suboxide by two-phase oxidn. of white phosphorus
carbon tetrachloride and water and isolation of the suboxide from the
aq. phase

5/6/24

003452406 WPI Acc No: 82-05985E/04

XRAM Acc No: C82-E05985

Redn. of trivalent iron in wet-process phosphoric acid by adding phosphorus sub-oxide as reducing agent

5/6/25

003450445 WPI Acc No: 82-05004J/49

XRAM Acc No: C82-J05004

Stabilising soln. for live attenuated vaccines e.g. yellow fever contg. phosphate buffer soln. contg. calcium and magnesium ions, lactose, sorbitol and aminoacid(s), pref. histidine and alanine

5/6/26

003444603 WPI Acc No: 82-02086E/02

XRAM Acc No: C82-E02086

Antiviral alkoxyalkanoyl ester(s) of adenine nucleoside cpds. with activity against e.g. herpes virus

5/6/27

003227503 WPI Acc No: 81-88061D/48

XRAM Acc No: C81-D88061

Base generating agent for heat developable photographic material comprises metal hydride oxyphosphorus cpd.

5/6/28

003209622 WPI Acc No: 81-70177D/39

XRAM Acc No: C81-D70177

Rust-inhibiting inorganic pigment comprises vitrified material contg. phosphorus and magnesium oxide(s)

5/6/29

003201847 WPI Acc No: 81-62398D/35

XRAM Acc No: C81-D62398

Getter for gas filling in halogen lamps using fluorine cycle esp. phosphorus nitrile difluoride, or phosphorus halogen isocyanate

5/6/30

003196366 WPI Acc No: 81-56918D/31

XRAM Acc No: C81-D56918

Flame retardant polymer compsn., e.g. polyurethane foam contg. halogenated trisphosphate cpd.

5/6/31

003195208 WPI Acc No: 81-55761D/31

XRAM Acc No: C81-D55761

Olefin polymerisation catalyst obtd. from magnesium halide and metal carboxylate, phosphorus halide, silicon cpd. and titanium halide;
POLYOLEFIN

5/6/32

003185613 WPI Acc No: 81-46164D/26

XRAM Acc No: C81-D46164

Dialkyl phosphate prodn. from phosphite by oxidn. with nitrous gas with addn. of halogen or inorganic halide to prevent monoalkyl phosphite formation

5/6/33

003184583 WPI Acc No: 81-45134D/25

XRAM Acc No: C81-D45134

Antihistamine quinoline derivs. are also central-nervous system
inhibitory agents and intermediates of thiocarbostyryl derivs.; CNS

5/6/34

003166605 WPI Acc No: 81-27147D/15

XRAM Acc No: C81-D27147

Treating viral infections in animals by injection of
malonato-ethylene-diamine-platinum etc.; MALONATE

5/6/35

003143079 WPI Acc No: 81-03620D/03

XRAM Acc No: C81-D03620

Triphosphate flame retardant for plastics and textiles prepd. from
phosphorus trihalide, glycol and oxirane; POLYETHYLENE POLYEPOXIDE
RESIN POLYESTER POLYURETHANE RUBBER CELLULOSE ESTER

?t s5/7/2 6

5/7/2

DIALOG(R)File 351:DERWENT WPI

(c)1995 Derwent Info Ltd. All rts. reserv.

004209196 WPI Acc No: 85-036076/06

XRAM Acc No: C85-015799

Vaccine prepn. against avian pox-diphtheria by inoculating columbar
stem into embryonated eggs, triturating membrane, sonic vibration,
re-dispersion and lyophilising

Patent Assignee: (BIOP-) CENT BIOPREP PASARI

Author (Inventor): PATRASCU I V; DANES L; VOINOVSKI E; CIOBANU M; CALARIU
C

Number of Patents: 001

Patent Family:

CC Number	Kind	Date	Week
RO 84572	A	840830	8506 (Basic)

Priority Data (CC No Date): RO 108083 (820706)

Abstract (Basic): RO 84572

In the prepn. of a vaccine against avian pox-diphtheria, the
columbar stem, registered in the collection of the Centre for Research
and Bio-preparations for Birds and Small Animals, Voluntari-Bucuresti,
at no. 103, is inoculated intra-alento-amniotically into embryonated
eggs, free from specific pathogenic germs. The modified membranes are
then triturated in an equal vol. of SPGA. After subjecting to sonic
vibration, the treatment is repeated 3 times consecutively, followed by
centrifuging at 4 deg.C.

The sediment is re-dispersed in SPGA and the sonic vibration
treatment is repeated. The prod. is then lyophilised by standard
methods. @(-pp)@

Derwent Class: B04; C03; D16;

Int Pat Class: A61K-039/28

5/7/6

DIALOG(R)File 351:DERWENT WPI

(c)1995 Derwent Info Ltd. All rts. reserv.

004002113 WPI Acc No: 84-147655/24

Related WPI Accession(s): 84-219196

XRAM Acc No: C84-062383

Vector-contg. chimeric gene prepn. - for use in expression of foreign
genes

Patent Assignee: (USDC) US DEPT OF COMMERCE; (USDC) US SEC OF COMMERCE

Author (inventor): HACKER, M; MOSS, J; SMITH, G L
Number of Patents: 007
Number of Countries: 011
Patent Family:

CC Number	Kind	Date	Week	
EP 110385	A	840613	8424	(Basic)
WO 8402077	A	840607	8425	
AU 8423424	A	840618	8439	
JP 60500518	W	850418	8522	
DK 8403710	A	840730	8526	
EP 110385	B1	930217	9307	
DE 3382659	G	930325	9313	

Priority Data (CC No Date): US 445451 (821130); US 445892 (821201)
Applications (CC,No,Date): EP 83111976 (831129); WO 83US1863 (831128); JP
84500057 (831129); EP 83111976 (831129); DE 3382659 (831129); EP
83111976 (831129)

Language: English

EP and/or WO Cited Patents: No-SR.Pub; 1.Jnl.Ref; EP 74808; EP 83286; US
4237224

Designated States

(National): AU; DK; JP

(Regional): CH; DE; FR; GB; IT; LI; NL; SE

Filing Details: DE3382659 Based on EP 110385

Abstract (Basic): EP 110385 A

Prepn. comprises (1) prepn. of a plasmid, cosmid or phage contg.
poxvirus DNA. The DNA comprises at least one transcriptional
regulatory sequence next to at least one restriction endonuclease site,
and DNA from a non-essential region of poxvirus genome flanking the
transcriptional regulatory sequence and the endonuclease site. And (2)
insertion of at least one protein coding sequence from a foreign gene
into the site next to the sequence. The poxvirus recombinants express
foreign genes, including DNA genes and DNA copies of RNA genes from
hepatitis B virus or A or non-A non B, influenza virus, herpes virus, F
and M disease virus, pathogenic bacteria, rickettsia, protozoa,
metazoa etc. The expression is efficient, and recombinant viruses can
be used for vaccine prodn. Dwg.0/0

Abstract (EP): 9307 EP 110385 B

A vector which can undergo homologous recombination in a poxvirus,
comprising: a chimeric gene which comprises at least one poxvirus
transcriptional regulatory sequence and, under the transcriptional
control of the regulatory sequence, at least one uninterrupted protein
coding sequence from a foreign gene, wherein the regulatory sequence
and the coding sequence are not separated by another transcriptional
regulatory sequence; and DNA, flanking the chimeric gene, from a
non-essential region of poxvirus genome. Dwg.0/0

Derwent Class: B04; D16;

Int Pat Class: A61K-039/12; C07K-015/00; C12N-007/00; C12N-009/10;
C12N-015/39; C12N-015/86; C12P-019/34; C12P-021/00

?save temp

Temp SearchSave "TB084" stored

?b \$55

06jun95 13:07:46 User208669 Session B255.2

\$22.20 0.100 Hrs File351

\$0.00 66 Type(s) in Format 6

\$10.00 5 Type(s) in Format 7

\$10.00 71 Types

\$0.00 View Fee

\$32.20 Estimated cost File351

\$1.20 SPRNTNET

\$33.40 Estimated cost this search

\$33.57 Estimated total session cost 0.105 Hrs.

File 155:MEDLINE(R) 1966-1995/Jul W4

(c) format only 1995 Knight-Ridder Info

set	items	description
---	-----	-----

?exs

Executing TB084

S1 1125604 PY=1981:1984

S2 6151 VACCINIA

1125604 S1

6151 S2

S3 495 S1 AND S2

S4 2525 POX?

1125604 S1

2525 S4

495 S3

S5 219 S1 AND S4 NOT S3

?s recomb?

S6 100874 RECOMB?

?s s3 and s6

495 S3

100874 S6

S7 51 S3 AND S6

?t s7/6/1-51

7/6/1

05830031 86131031

Recombinant vaccinia viruses as new live vaccines.

7/6/2

05554412 85170412

Genetically engineered poxviruses: a novel approach to the construction of live vaccines.

7/6/3

05447758 85063758

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

7/6/4

05445505 85061505

Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

7/6/5

05396720 85012720

Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells.

7/6/6

05371612 84295612

Live recombinant vaccinia virus protects chimpanzees against hepatitis B.

7/6/7

05371600 84295600

Recombinant vaccinia for prevention of hepatitis B [news]

7/6/8

05368442 84292442

Regulation of expression and nucleotide sequence of a late vaccinia virus gene.

7/6/9

05310083 84234083

Recombinant technology in medical research and therapeutics.

7/6/10

05248200 84172200

Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus.

7/6/11

05214781 84138781

General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

7/6/12

05212566 84136566

Contribution of molecular biology to the understanding and control of microbial infections.

7/6/13

05195434 84119434

Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

7/6/14

05185543 84109543

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA.

7/6/15

05175534 84099534

Physical mapping of vaccinia virus temperature-sensitive mutations.

7/6/16

05166421 84090421

Mapping of the vaccinia virus DNA polymerase gene by marker rescue and cell-free translation of selected RNA.

7/6/17

05146785 84070785

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

7/6/18

05127803 84051803

Biochemical and genetic characterization of vaccinia virus temperature-sensitive mutants with DNA- and DNA^f-phenotypes.

7/6/19

05107413 84031413

Biogenesis of vaccinia: analysis by three-factor crosses reveals mutual influence on stability of drug resistance and temperature sensitivity when both markers occur in some recombinant virus isolates.

7/6/20

05087038 84011038

Marker rescue of temperature-sensitive mutations of vaccinia virus WR: correlation of genetic and physical maps.

7/6/21

05070819 83303819

Selection for temperature-sensitive mutations in specific vaccinia virus genes: isolation and characterization of a virus mutant which encodes a phosphonoacetic acid-resistant, temperature-sensitive DNA polymerase.

7/6/22

05066974 83299974

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.

7/6/23

05031041 83264041

Smallpox conquered, vaccinia directed against hepatitis B [news]

7/6/24

04988605 83221605

Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene.

7/6/25

04966355 83199355

[Comparative study of the biological properties of plasmid and natural human interferons]

Sravnitel'noe izuchenie biologicheskikh svoistv plazmidnykh i prirodnykh chelovecheskikh interferonov.

7/6/26

04966236 83199236

Mapping thymidine kinase-deficient mutants of vaccinia virus by marker rescue with hybrid plasmid DNAs containing portions of the HindIII-J fragment of virus DNA.

7/6/27

04956370 83189370

Structural proteins and cell-free translation products of total RNA and hybrid-selected RNA from two DNA variants of vaccinia virus.

7/6/28

04934508 83167508

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

7/6/29

04930022 83163022

Neonatal tolerance of major histocompatibility complex antigens alters Ir gene control of the cytotoxic T cell response to vaccinia virus.

7/6/30
04884689 83117689
Vaccinia virus: a selectable eukaryotic cloning and expression vector.

7/6/31
04884629 83117629
Sequence of terminal regions of cowpox virus DNA: arrangement of repeated and unique sequence elements.

7/6/32
04879225 83112225
Vaccinia virus thymidine kinase and neighboring genes: mRNAs and polypeptides of wild-type virus and putative nonsense mutants.

7/6/33
04877119 83110119
A poxvirus antigen associated with pathogenicity for rabbits.

7/6/34
04866270 83099270
Antiviral and side effects of interferons produced by recombinant DNA techniques as tested in rhesus monkeys.

7/6/35
04836274 83069274
Gene-transfer, stability, and biochemical properties of animal cells transformed with vaccinia DNA.

7/6/36
04831507 83064507
Sequence homologies of diverse length tandem repetitions near ends of vaccinia virus genome suggest unequal crossing over.

7/6/37
04826924 83059924
Complete nucleotide sequences of two adjacent early vaccinia virus genes located within the inverted terminal repetition.

7/6/38
04826837 83059837
Isolation and genetic characterization of temperature-sensitive mutants of vaccinia virus WR.

7/6/39
04782005 83015005
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.

7/6/40
04674027 82217027
Colinearity of RNAs with the vaccinia virus genome: anomalies with two complementary early and late RNAs result from a small deletion or rearrangement within the inverted terminal repetition.

7/6/41
04658031 82201031
Complementation and genetic linkage between vaccinia virus temperature-sensitive mutants.

7/6/42
04631645 82174645
Molecular genetics of vaccinia virus: demonstration of marker rescue.

7/6/43
04631565 82174565
Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA.

7/6/44
04490266 82033266
Extension of the transcriptional and translational map of the left end of the vaccinia virus genome to 21 kilobase pairs.

7/6/45
04490265 82033265
Transcriptional and translational mapping of a 6.6-kilobase-pair DNA fragment containing the junction of the terminal repetition and unique sequence at the left end of the vaccinia virus genome.

7/6/46
04448912 81276912
Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus.

7/6/47
04442727 81270727
Comparative antiviral efficiency of leukocyte and bacterially produced human alpha-interferon in rhesus monkeys.

7/6/48
04416280 81244280
Target antigen of vaccinia-infected cells recognized by virus-specific cytotoxic T lymphocytes.

7/6/49
04399647 81227647
Host range deletion mutant of vaccinia virus defective in human cells.

7/6/50
04371504 81199504
Instability and reiteration of DNA sequences within the vaccinia virus genome.

7/6/51
04342708 81170708
Hybridization selection and cell-free translation of mRNA's encoded within the inverted terminal repetition of the vaccinia virus genome.
?t s7/7/8 11 17 22 28 30 35 37 39

7/7/8

05368442 84292442

Regulation of expression and nucleotide sequence of a late vaccinia virus gene.

Weir JP; Moss B

J Virol (UNITED STATES) Sep 1984, 51 (3) p662-9, ISSN 0022-538X

Journal Code: KCV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

A subset of vaccinia virus genes are expressed only after DNA replication. To investigate the regulation of such transcriptional units, a representative gene encoding a major late polypeptide (Mr, 28,000) was mapped and sequenced. Translatable mRNAs were heterogeneous in length and overlapped several early genes downstream. The 5' end of the message was located, and the DNA segment upstream was excised and ligated to the coding sequence of the easily assayable procaryotic chloramphenicol acetyltransferase gene. The resulting chimeric gene was recombined into the thymidine kinase locus of the vaccinia virus genome, and infectious recombinant virus was isolated. Both the time of chloramphenicol acetyltransferase synthesis in infected cells and the requirement for DNA replication indicate that the sequence upstream of the late gene contains cis-acting transcriptional regulatory signals.

7/7/11

DIALOG(R) File 155: MEDLINE(R)

(c) format only 1995 Knight-Ridder Info. All rts. reserv.

05214781 84138781

General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Mackett M; Smith GL; Moss B

J Virol (UNITED STATES) Mar 1984, 49 (3) p857-64, ISSN 0022-538X

Journal Code: KCV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The production and selection of infectious vaccinia virus recombinants expressing foreign genes was facilitated by the construction of plasmid vectors. These vectors contain all or part of the vaccinia virus thymidine kinase (TK) gene interrupted by multiple unique restriction endonuclease sites placed adjacent to the TK promoter or another promoter translocated within the TK gene. The insertion of a continuous coding sequence for a foreign protein at one of the unique restriction endonuclease sites juxtaposes the transcriptional start site of a vaccinia promoter and the translational start site of a foreign gene. After transfection of vaccinia virus-infected cells with such plasmids, homologous recombination occurs between the vaccinia virus sequences flanking the chimeric gene and the same sequences within the virus genome. Recombinants formed in this manner have the chimeric gene inserted within the body of the vaccinia virus TK gene under control of a vaccinia virus promoter. Since recombinants have an interrupted TK gene, they are selected on the basis of their TK- phenotype and then checked for the presence and expression of the foreign gene. Infectious recombinant viruses expressing the procaryotic enzyme chloramphenicol acetyltransferase were constructed to optimize the system. The absence of chloramphenicol acetyltransferase activity in uninfected cells or in cells infected with wild-type vaccinia virus and the availability of a sensitive and quantitative enzyme assay allowed an estimation of the relative strengths of various promoter constructs. The expression of chloramphenicol acetyltransferase was detected within 1 h after infection of cells with recombinant virus, reflecting the early nature of the promoters used.

7/7/17

DIALOG(R) File 155:MEDLINE(R)
(c) format only 1995 Knight-Ridder Info. All rts. reserv.

05146785 84070785

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

Smith GL; Murphy BR; Moss B

Proc Natl Acad Sci U S A (UNITED STATES) Dec 1983, 80 (23) p7155-9,
ISSN 0027-8424 Journal Code: PV3

Languages: ENGLISH

Document type: JOURNAL ARTICLE

A DNA copy of the influenza virus hemagglutinin gene, derived from influenza virus A/Jap/305/57 (H2N2) was inserted into the genome of vaccinia virus under the control of an early vaccinia virus promoter. Tissue culture cells infected with the purified recombinant virus synthesized influenza hemagglutinin, which was glycosylated and transported to the cell surface where it could be cleaved with trypsin into HA1 and HA2 subunits. Rabbits and hamsters inoculated intradermally with recombinant virus produced circulating antibodies that inhibited hemagglutination by influenza virus. Furthermore, vaccinated hamsters achieved levels of antibody similar to those obtained upon primary infection with influenza virus and were protected against respiratory infection with the A/Jap/305/57 influenza virus.

7/7/22

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1995 Knight-Ridder Info. All rts. reserv.

05066974 83299974

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.

Panicali D; Davis SW; Weinberg RL; Paoletti E

Proc Natl Acad Sci U S A (UNITED STATES) Sep 1983, 80 (17) p5364-8,
ISSN 0027-8424 Journal Code: PV3

Contract/Grant No.: GM23853

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Recombinant vaccinia viruses containing the cloned hemagglutinin (HA) gene from influenza virus were constructed. The biological activity of these poxvirus vectors was demonstrated both in vitro and in vivo. Expression of HA in cells infected with recombinant vaccinia was detected by using specific anti-HA antiserum and 125I-labeled protein A, showing that HA synthesized under the regulation of vaccinia virus was antigenic. Immunization of rabbits with these recombinant poxviruses resulted in the production of antibodies reactive with authentic influenza HA as detected by radioimmunoassay, by inhibition of HA erythrocyte agglutination, and by neutralization of influenza virus infectivity. The production of antibodies directed against influenza HA suggested that the HA gene expressed in vaccinia is immunogenic. These data indicate the potential of genetically engineered poxviruses for use as generic live vaccine vehicles that have both human and veterinary applications.

7/7/28

DIALOG(R) File 155:MEDLINE(R)

(c) format only 1995 Knight-Ridder Info. All rts. reserv.

04934508 83167508

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Smith GL; Mackett M; Moss B

Nature (ENGLAND) Apr 7 1983, 302 (5908) p490-5, ISSN 0028-0836
Journal Code: NSC

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Potential live vaccines against hepatitis B virus have been produced. The coding sequence for hepatitis B virus surface antigen (HBsAg) has been inserted into the vaccinia virus genome under control of vaccinia virus early promoters. Cells infected with these vaccinia virus recombinants synthesize and excrete HBsAg and vaccinated rabbits rapidly produce antibodies to HBsAg.

7/7/30

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1995 Knight-Ridder Info. All rts. reserv.

102-b

04884689 83117689

Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Mackett M; Smith GL; Moss B

Proc Natl Acad Sci U S A (UNITED STATES) Dec 1982, 79 (23) p7415-9,

ISSN 0027-8424 Journal Code: PV3

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Foreign DNA was inserted into two nonessential regions of the vaccinia virus genome by homologous recombination in cells infected with virus and transfected with plasmids containing the foreign DNA elements flanked by vaccinia virus DNA. Thymidine kinase-negative (TK-) recombinants were selected after inserting foreign DNA into the coding region of the TK gene of wild-type vaccinia virus; TK+ recombinants were selected after inserting the herpesvirus TK gene into TK- mutants of vaccinia virus. For TK+ expression, it was necessary to insert a 275-base-pair DNA fragment containing the initiation site and sequences upstream of an early vaccinia virus transcript next to the coding sequences of the herpesvirus gene. The unique ability of the herpesvirus TK to phosphorylate 125I-labeled deoxycytidine provided independent confirmation of gene expression. These studies demonstrate the use of vaccinia virus as a selectable cloning and expression vector, confirm the map location of the vaccinia virus TK gene, and provide initial information regarding the location of vaccinia virus transcriptional regulatory sequences.

7/7/35

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1995 Knight-Ridder Info. All rts. reserv.

04836274 83069274

Gene-transfer, stability, and biochemical properties of animal cells transformed with vaccinia DNA.

Pellicer A; Esteban M

Virology (UNITED STATES) Oct 30 1982, 122 (2) p363-80, ISSN 0042-6822

Journal Code: XEA

Contract/Grant No.: ROI AI 16780; RR 05399

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/7/37

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1995 Knight-Ridder Info. All rts. reserv.

04826924 83059924

Complete nucleotide sequences of two adjacent early vaccinia virus genes located within the inverted terminal repetition.

Venkatesan S; Gershowitz A; Moss B

J Virol (UNITED STATES) Nov 1982, 44 (2) p637-46, ISSN 0022-538X

Journal Code: KCV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/7/39

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1995 Knight-Ridder Info. All rts. reserv.

Inventors

04782005 83015005

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.

Panicali D; Paoletti E

Proc Natl Acad Sci U S A (UNITED STATES) Aug 1982, 79 (16) p4927-31,
ISSN 0027-8424 Journal Code: PV3

Contract/Grant No.: GM23853

Languages: ENGLISH

Document type: JOURNAL ARTICLE

We have constructed recombinant vaccinia viruses containing the thymidine kinase gene from herpes simplex virus. The gene was inserted into the genome of a variant of vaccinia virus that had undergone spontaneous deletion as well as into the 120-megadalton genome of the large prototypic vaccinia variant. This was accomplished via in vivo recombination by cotransfection of eukaryotic tissue culture cells with cloned BamHI-digested thymidine kinase gene from herpes simplex virus containing flanking vaccinia virus DNA sequences and infectious rescuing vaccinia virus. Pure populations of the recombinant viruses were obtained by replica filter techniques or by growth of the recombinant virus in biochemically selective medium. The herpes simplex virus thymidine kinase gene, as an insert in vaccinia virus, is transcribed in vivo and in vitro, and the fidelity of in vivo transcription into a functional gene product was detected by the phosphorylation of 5-[125I]iodo-2'-deoxycytidine.

?log hold

06jun95 13:14:10 User208669 Session B255.3

\$1.74 0.116 Hrs File155

\$0.00 51 Type(s) in Format 6

\$1.26 9 Type(s) in Format 7

\$1.26 60 Types

\$2.00 View Fee

\$5.00 Estimated cost File155

\$1.39 SPRNTNET

\$6.39 Estimated cost this search

\$39.96 Estimated total session cost 0.221 Hrs.

Logoff: level 38.03.03 B 13:14:10

DIALOG DISCONNECTED 00 40 00:00:12:43 1058 32

@

s hepatitis and surface antigen
3116 HEPATITIS
992055 SURFACE
9297 ANTIGEN
812 SURFACE ANTIGEN
(SURFACE(W)ANTIGEN)

L1 473 HEPATITIS AND SURFACE ANTIGEN

=> d 11 850-473

450. 4,162,192, Jul. 24, 1979, Method for purification of HBs antigen; Kyosuke Mizuno, et al., 435/239; 424/89

451. 4,152,411, May 1, 1979, High specific activity labeled substances; Roy F. Schall, Jr., 436/545, 500, 528, 546, 800

452. 4,145,406, Mar. 20, 1979, Specific binding - adsorbent assay method and test means; Lloyd A. Schick, et al., 436/541, 542, 804, 820

453. 4,140,761, Feb. 20, 1979, Modification of **hepatitis** B virus infection in chronic carriers of **hepatitis** B **surface** **antigen**;
John L. Gerin, et al., 424/85.4, 86; 514/889

454. 4,138,287, Feb. 6, 1979, Purifying and isolating method for **hepatitis** virus to use in preparing vaccine; Lars-Olov Andersson, et al., 435/239; 424/89

455. 4,129,646, Dec. 12, 1978, Isolating **hepatitis** B Dane particles; William J. McAleer, et al., 424/89

456. 4,118,479, Oct. 3, 1978, Vaccine for active immunization containing **hepatitis** B **surface** **antigen** and associated antigen; Alfred M. Prince, et al., 424/89

457. 4,118,478, Oct. 3, 1978, Vaccine manufacture for active immunization containing **hepatitis** B **surface** **antigen** and associated antigen; Alfred M. Prince, et al., 424/89

458. 4,118,477, Oct. 3, 1978, **Hepatitis** B antigen; William J. McAleer, et al., 424/89

459. 4,113,712, Sep. 12, 1978, HBsAG Particle composed of single polypeptide subunits and the preparation procedure; Satoshi Funakoshi, 530/380; 424/86, 89; 436/543, 547, 820, 826; 530/350, 392, 394, 405, 406, 413, 417, 806, 831

460. 4,102,996, Jul. 25, 1978, Method of preparing **hepatitis** B core antigen; William J. McAleer, et al., 424/89; 435/5, 7.92, 7.95, 239, 961

461. 4,100,267, Jul. 11, 1978, Method of detecting **hepatitis** B core antigen and antibody; Eugene Douglas Shaw, 436/516; 424/86, 89, 93T; 436/820

462. 4,088,748, May 9, 1978, **Hepatitis** B **surface** **antigen**;
William J. McAleer, et al., 424/89; 435/239

463. 4,087,519, May 2, 1978, Medicament for the treatment of **hepatitis** and/or acute or chronic infections due to the virus of **hepatitis** B; Christian G. Trepo, 424/86, 89; 530/380, 389.4, 390.5, 413, 414, 421, 830, 851

464. 4,053,284, Oct. 11, 1977, Continuous flow apparatus for biological testing; Nancy Ann Posch, 422/69; 15/302, 304; 134/167R; 424/1.1; 435/5, 291, 975; 436/527, 531, 532, 807, 811, 820 [IMAGE AVAILABLE]

465. 4,038,378, Jul. 26, 1977, Radioimmunoassay for **hepatitis** B antigen; Gyaneshwar Prasad Khare, 436/523, 804, 810, 820

466. 4,024,243, May 17, 1977, Process for isolating **hepatitis** B antigen; William J. McAleer, et al., 530/380; 424/89; 435/239; 530/830

467. 4,021,540, May 3, 1977, Preparation of a **hepatitis** B immune globulin and use thereof as a prophylactic material; William Pollack, et al., 424/86; 436/544, 545, 804, 820; 530/389.4, 830, 831

468. 4,017,360, Apr. 12, 1977, Method for purifying **hepatitis** B antigen; Alexander U. Bertland, et al., 435/269; 424/89; 435/212

469. 4,016,043, Apr. 5, 1977, Enzymatic immunological method for the determination of antigens and antibodies; Antonius H. W. M. Schuurs, et al., 435/5, 7.32, 7.94, 28, 810, 964, 966, 971, 975

470. 3,994,870, Nov. 30, 1976, Purification of **hepatitis** B **surface** **antigen**;; A. Robert Neurath, et al., 530/380; 210/656; 424/86, 89; 435/180, 239; 436/543, 820; 530/392, 394, 395, 396, 403, 413, 806, 826

471. 3,992,517, Nov. 16, 1976, Detection of **hepatitis** B **surface** **antigen** by latex agglutination; George E. Lowke, et al., 436/509; 424/86, 89, 93T; 436/534, 820; 530/806, 815, 816

472. 3,991,181, Nov. 9, 1976, Injectable stroma free hemoglobin solution and its method of manufacture; John Doczi, 530/385

473. 3,976,767, Aug. 24, 1976, Purification of **hepatitis** B **surface** **antigen** by chromatography on agarose containing aminoalkyl residues; A. Robert Neurath, 424/89; 210/635

=> e valenzuela, p?/in

E1	3	VALENZUELA, JAVIER A/IN
E2	1	VALENZUELA, LUIS/IN
E3	0 -->	VALENZUELA, P?/IN
E4	5	VALENZUELA, PABLO/IN
E5	11	VALENZUELA, PABLO D T/IN
E6	1	VALENZUELA, PABLO V/IN
E7	1	VALENZUELA, RAFAEL L/IN
E8	1	VALENZUELA, REINALDO/IN
E9	1	VALEO, ERNEST J/IN
E10	3	VALEO, ROY/IN
E11	1	VALERA, MARCO/IN
E12	1	VALERE, EUGENE/IN

=> s e4

L2	5	"VALENZUELA, PABLO"/IN
----	---	------------------------

=> s e5

L3	11	"VALENZUELA, PABLO D T"/IN
----	----	----------------------------

=> s e6

L4	1	"VALENZUELA, PABLO V"/IN
----	---	--------------------------

=> d 12 1-5 ti

US PAT NO:	5,171,680 [IMAGE AVAILABLE]	L2: 1 of 5
TITLE:	Superoxide dismutase analogs having novel binding properties	

US PAT NO:	5,096,825 [IMAGE AVAILABLE]	L2: 2 of 5
TITLE:	Gene for human epidermal growth factor and synthesis and expression thereof	

US PAT NO:	5,045,455 [IMAGE AVAILABLE]	L2: 3 of 5
TITLE:	Factor VIII:C cDNA cloning and expression	

US PAT NO: 5,004,804 [IMAGE AVAILABLE] L2: 4 of 5
TITLE: Method and composition for preparation of factor VIIIC

US PAT NO: 4,716,117 [IMAGE AVAILABLE] L2: 5 of 5
TITLE: Monoclonal antibodies to factor VIIIC

=> d 14 ti

US PAT NO: 3,912,595 L4: 1 of 1
TITLE: Method of purifying enzymes using boronic acids covalently bonded to an insoluble support

=> d 13 1-11 ti

US PAT NO: 5,171,568 [IMAGE AVAILABLE] L3: 1 of 11
TITLE: Recombinant herpes simplex gb-gd vaccine

US PAT NO: 5,098,704 [IMAGE AVAILABLE] L3: 2 of 11
TITLE: Hepatitis surface antigen particle vaccine

US PAT NO: 5,015,575 [IMAGE AVAILABLE] L3: 3 of 11
TITLE: Hybrid DNA synthesis of insulin

US PAT NO: 4,914,026 [IMAGE AVAILABLE] L3: 4 of 11
TITLE: Alpha factor leader sequence directed secretion of insulin

US PAT NO: 4,880,734 L3: 5 of 11
TITLE: Eukaryotic regulatable transcription

US PAT NO: 4,876,197 L3: 6 of 11
TITLE: Eukaryotic regulatable transcription

US PAT NO: 4,820,642 L3: 7 of 11
TITLE: Amplified expression vector

US PAT NO: 4,769,238 L3: 8 of 11
TITLE: Synthesis of human virus antigens by yeast

US PAT NO: 4,722,840 L3: 9 of 11
TITLE: Hybrid particle immunogens

US PAT NO: 4,618,578 L3: 10 of 11
TITLE: Expression of glycoprotein D of herpes simplex virus

US PAT NO: 4,510,245 L3: 11 of 11
TITLE: Adenovirus promoter system

=> d 13 2 10 8 bib ab ccls

US PAT NO: 5,098,704 [IMAGE AVAILABLE] L3: 2 of 11
DATE ISSUED: Mar. 24, 1992
TITLE: Hepatitis surface antigen particle vaccine
INVENTOR: **Pablo D. T. Valenzuela**, San Francisco, CA
ASSIGNEE: Chiron Corporation, Emeryville, CA (U.S. corp.)
APPL-NO: 07/266,795
DATE FILED: Nov. 3, 1988
ART-UNIT: 186
PRIM-EXMR: Garnette D. Draper
LEGAL-REP: Morrison & Foerster

US PAT NO: 5,098,704 [IMAGE AVAILABLE] L3: 2 of 11

ABSTRACT:

Vaccines are provided produced by hybrid DNA technology for Hepatitis B

virus comprising Hepatitis B surface antigen particles containing a human polyalbumin binding site receptor. Constructs are provided for expression of the vaccine protein, which upon transformation in an appropriate host results in the production of particles useful as vaccines.
US-CL-CURRENT: 424/89, 85.8, 86, 88

US PAT NO: 4,618,578 L3: 10 of 11
DATE ISSUED: Oct. 21, 1986
TITLE: Expression of glycoprotein D of herpes simplex virus
INVENTOR: Rae L. Burke, San Francisco, CA
Mickey S. Urdea, San Francisco, CA
Pablo D. T. Valenzuela, San Francisco, CA
ASSIGNEE: Chiron Corporation, Emeryville, CA (U.S. corp.)
APPL-NO: 06/631,669
DATE FILED: Jul. 17, 1984
ART-UNIT: 127
PRIM-EXMR: Blondel Hazel
LEGAL-REP: Leydig, Voit & Mayer

US PAT NO: 4,618,578 L3: 10 of 11

ABSTRACT:

Methods and compositions are provided for the efficient production in yeast of polypeptides which are immunologically cross-reactive with glycoprotein D of the herpes simplex virus. Synthetic DNA fragments encoding for a portion of the glycoprotein, and the naturally-occurring gene encoding for the glycoprotein and portions thereof, are expressed on plasmids in yeast. Secretion may be provided by including a secretory leader and signal processing sequence derived from the .alpha.-factor gene. Alternatively, the genes may be expressed intracellularly under the transcriptional control of a promoter derived from a gene in the yeast glycolytic pathway.

E. coli strains HB101 containing plasmids pYHS109 and pYHS118 were deposited at the American Type Culture Collection on July 11, 1984, and granted accession nos. 39762 and 39763, respectively.

US-CL-CURRENT: 435/69.3, 69.9, 172.3, 320.1; 536/27; 930/224; 935/12, 27,
28

US PAT NO: 4,769,238 L3: 8 of 11
DATE ISSUED: Sep. 6, 1988
TITLE: Synthesis of human virus antigens by yeast
INVENTOR: William J. Rutter, San Francisco, CA
Pablo D. T. Valenzuela, San Francisco, CA
Benjamin D. Hall, Bellevue, WA
Gustav Ammerer, Seattle, WA
ASSIGNEE: The Regents of the University of California, CA (U.S. corp.)
APPL-NO: 06/821,146
DATE FILED: Dec. 12, 1985
ART-UNIT: 124
PRIM-EXMR: John E. Tarcza
LEGAL-REP: Ciotti & Murashige, Irell & Manella

US PAT NO: 4,769,238 L3: 8 of 11

ABSTRACT:

The present invention relates to synthesis of HBsAg in yeast. Yeast expression vectors comprising a yeast promoter, ADHI, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector.

Using the described yeast vector, the successful synthesis of HBsAg by yeast has been achieved. The product is antigenic (reactive with anti-HBsAg), and a substantial portion is found associated with particles

identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBsAg synthesized by yeast has identical sedimentation behavior to purified, naturally-occurring HBsAg particles purified from Alexander cells as measured by sucrose gradient sedimentation. The present invention demonstrates synthesis and assembly of a higher ordered multi-component structure resulting from expression of a heterologous DNA coding segment in a microorganism.

US-CL-CURRENT: 424/89; 435/69.3, 172.3, 256; 530/350, 806, 824, 826;
935/12, 28, 37, 69

=> log y

E1	4	MOSS, ARTHUR Z/IN
E2	1	MOSS, BARRY/IN
E3	0 -->	MOSS, BERN?/IN
E4	9	MOSS, BERNARD/IN
E5	2	MOSS, BILLY/IN
E6	11	MOSS, BRIAN F/IN
E7	1	MOSS, BRIAN YOXALL/IN
E8	3	MOSS, BRYAN T/IN
E9	1	MOSS, BY RACHEL TOMLINSON EXECUTRIX/IN
E10	1	MOSS, C EUGENE/IN
E11	3	MOSS, C WILLIAM/IN
E12	8	MOSS, CHARLES A/IN

=> s e4

L1 9 "MOSS, BERNARD"/IN

=> d 11 1-9 ti

US PAT NO:	5,206,353 [IMAGE AVAILABLE]	L1: 1 of 9
TITLE:	CD-4/cytotoxic gene fusions	
US PAT NO:	5,187,268 [IMAGE AVAILABLE]	L1: 2 of 9
TITLE:	Gene encoding an anti-complement protein from vaccinia	
US PAT NO:	5,164,313 [IMAGE AVAILABLE]	L1: 3 of 9
TITLE:	Recombinant vaccinia virus encoding cytochromes P-450	
US PAT NO:	5,157,110 [IMAGE AVAILABLE]	L1: 4 of 9
TITLE:	Synthetic, anti-complement protein	
US PAT NO:	5,151,509 [IMAGE AVAILABLE]	L1: 5 of 9
TITLE:	Gene encoding serine protease inhibitor	
US PAT NO:	5,135,855 [IMAGE AVAILABLE]	L1: 6 of 9
TITLE:	Rapid, versatile and simple system for expressing genes in eukaryotic cells	
US PAT NO:	5,126,251 [IMAGE AVAILABLE]	L1: 7 of 9
TITLE:	Stable mammalian cell line expressing a bacteriophage RNA polymerase	
US PAT NO:	4,772,427 [IMAGE AVAILABLE]	L1: 8 of 9
TITLE:	Post-foaming gel shower product	
US PAT NO:	4,738,846 [IMAGE AVAILABLE]	L1: 9 of 9
TITLE:	Vaccine for vesicular stomatitis virus	

=> d 11 6 and 9 bib ab ccls

'AND' IS NOT A VALID FORMAT FOR FILE 'USPAT'

ENTER DISPLAY FORMAT (CIT):6 9 bib ab ccls

'6' IS NOT A VALID FORMAT FOR FILE 'USPAT'

'9' IS NOT A VALID FORMAT FOR FILE 'USPAT'

YOU HAVE RECEIVED THIS ERROR MESSAGE 2 CONSECUTIVE TIMES

The following are valid formats:

PNO ----- Patent Number

PAT ----- Patent Number, Issue Date, and Current Original
Reference Classification

CIT ----- Patent Number, Issue Date, Title,
First Inventor Name, and Current Classifications

LEG ----- Patent Number, Issue Date, Title, Inventor, Assignee,
Appl. Number, Filing Date, Art Unit, Primary Examiner,
Legal Rep., Rule 47 Indicator, Attorney Reg. Number

REF ----- Classification and Reference Information

DATE ----- PCT Information and all dates from Front Page

FC1 ----- Alias for the CARS Format
 BIB ----- Alias for the LEG Format
 FRO ----- Front Page Information, Art Unit, and Current
 Classifications
 ALL ----- Entire Patent and Key words assigned
 FUL ----- Alias for the ALL Format
 SPC ----- Alias for the ALL Format
 CLS ----- Patent Number and Current Classification
 PN ----- Patent Number
 OCC ----- Occurrence Count
 AB ----- Abstract
 FD ----- Application Filing Date
 ADU ----- Application Filing Date
 R ----- R(_lf^, JZ-E-WKVQ. L
 ART ----- Art Unit
 AS ----- Assignee Information
 ATT ----- Attorney, Agent or Firm
 BSUM ----- Summary
 CCLS ----- Current Classification
 CLMS ----- Claims Information
 D371 ----- PCT 371 Date
 DD ----- Disclaimer Date
 DETD ----- Detail Description
 DRWD ----- Drawing Description
 E102 ----- PCT 102(e) Date
 ECL ----- Exemplary Claim Number
 FREF ----- Foreign Patent References Cited
 FS ----- Field of Search Subclasses
 GI ----- Government Interest Text Data
 ICLS ----- Issue Classification
 IN ----- Inventor Information
 IPC ----- International ClassificationPatent
 TI ----- Title
 UREF ----- U. S. Patent References Cited
 XA ----- Assistant Examinerd 11 6 9 bib ab ccls

US PAT NO: 5,135,855 [IMAGE AVAILABLE] L1: 6 of 9
 DATE ISSUED: Aug. 4, 1992
 TITLE: Rapid, versatile and simple system for expressing genes in
 eukaryotic cells
 INVENTOR: **Bernard Moss**, Bethesda, MD
 Thomas Fuerst, Gaithersburg, MD
 Orna Elroy-Stein, Rockville, MD
 ASSIGNEE: The United States of America as represented by the
 Department of Health and Human Services, Bethesda, MD
 (U.S. govt.)
 APPL-NO: 07/376,687
 DATE FILED: Jul. 7, 1989
 ART-UNIT: 185
 PRIM-EXMR: Richard A. Schwartz
 ASST-EXMR: S. L. Nolan
 LEGAL-REP: Foley & Lardner

US PAT NO: 5,135,855 [IMAGE AVAILABLE] L1: 6 of 9

ABSTRACT:
 An efficient, versatile and simple expression system which confers
 cap-independent translation to prokaryotic RNAs in eukaryotic cells has
 been described. The utility of recombinant vaccinia virus for this
 purpose has been illustrated.
 US-CL-CURRENT: 435/69.1; 935/34, 36, 60, 70

US PAT NO: 4,738,846 [IMAGE AVAILABLE] L1: 9 of 9
 DATE ISSUED: Apr. 19, 1988

TITLE: Vaccine for vesicular stomatitis virus
INVENTOR: John K. Rose, Solana Beach, CA
Bernard Moss, Bethesda, MD
Tilahun Yilma, Pullman, WA
Michael Mackett, Rusholme, England
ASSIGNEE: The Salk Institute for Biological Studies, San Diego, CA
(U.S. corp.)
APPL-NO: 06/645,998
DATE FILED: Aug. 30, 1984
ART-UNIT: 124
PRIM-EXMR: Margaret Moskowitz
LEGAL-REP: Fitch, Even, Tabin & Flannery

US PAT NO: 4,738,846 [IMAGE AVAILABLE] L1: 9 of 9

ABSTRACT:

Synthetic vaccines for both the Indiana and New Jersey serotypes of vesicular stomatitis virus are provided. Recombinant vaccinia viruses are created with DNA sequences which encode antigenically active VSV proteins. Vaccinia virus sequences are inserted in plasmids and DNA sequences corresponding to encoding portions of the VSV genome are inserted into the plasmids with flanking vaccinia virus sequences. In cells transformed with such plasmids and also infected with vaccinia virus, homologous recombination occurs, producing the modified vaccinia viruses which act as vaccines encoding VSV proteins and inducing anti-VSV immune responses in inoculated animals.

US-CL-CURRENT: 424/87, 93A; 435/172.3, 235.1; 935/12, 32, 57, 65

=> d 11 7 bib ab ccls

US PAT NO: 5,126,251 [IMAGE AVAILABLE] L1: 7 of 9
DATE ISSUED: Jun. 30, 1992
TITLE: Stable mammalian cell line expressing a bacteriophage RNA polymerase
INVENTOR: **Bernard Moss**, Bethesda, MD
Orna Elroy-Stein, Rockville, MD
ASSIGNEE: The United States of America as represented by the
Secretary of the Department of Health and Human Services
, Washington, DC (U.S. govt.)
APPL-NO: 07/485,871
DATE FILED: Mar. 1, 1990
ART-UNIT: 185
PRIM-EXMR: Robert A. Wax
ASST-EXMR: S. L. Nolan
LEGAL-REP: Cushman, Darby & Cushman

US PAT NO: 5,126,251 [IMAGE AVAILABLE] L1: 7 of 9

ABSTRACT:

The present invention relates to a eukaryotic cell line which expresses a foreign RNA polymerase gene. The invention further relates to a method of expressing a foreign protein in a eukaryotic environment utilizing the cell line. The present invention allows for the expression of a foreign protein in a eukaryotic cell without requiring transfecting or infecting the cell with a vector carrying the RNA polymerase gene.

US-CL-CURRENT: 435/69.1, 240.2; 935/34, 60, 70

=> log y

cl

ds

Set	Items	Description
S1	5454	VACCINIA
S2	9618	GALACTOSIDASE
S3	5828	VIRION
S4	3	S1 AND S2 AND S3

?t s4/7/3

4/7/3

06688163 88333163

Vaccinia virus recombinants expressing an 11-kilodalton beta-galactosidase fusion protein incorporate active beta-galactosidase in virus particles.

Huang C; Samsonoff WA; Grzelecki A

Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany 12201.

J Virol Oct 1988; 62 (10) p3855-61, ISSN 0022-538X Journal Code: KCV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Recombinant plasmids in which vaccinia virus transcriptional regulatory sequences were fused to the Escherichia coli lacZ gene were constructed for insertion of the lacZ gene into the vaccinia virus genome. beta-Galactosidase (beta-gal) was found in some purified recombinant vaccinia virions. By enzyme activity, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and microscopic techniques, the evidence suggested that beta-gal accounted for 5% of the total protein in the virion. These recombinant viruses were constructed so that a portion of the coding sequences of a late vaccinia virus structural polypeptide was fused to the amino terminus of beta-gal to produce the fusion protein. Removal of the coding sequences resulted in the complete loss of beta-gal activity. This demonstrated that a vaccinia virus DNA segment from a late structural gene is responsible for the incorporation of beta-gal into the virion.

?

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.